Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: GlobeNewswire
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective study conducted by Leiden University Medical Center (LUMC) in The Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, were presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting this week. The study—Percutaneous Hepatic Perfusion in Patients with Unresectable Liver Metastases from Ocular Melanoma using Delcath Systems’ Second Generation (GEN 2) Hemofiltration System: A Prospective Phase 2 Study—was conducted by researchers at LUMC reported by T.S. Meijer, MD. The study prospectively evaluated tumor response rate, safety, overall survival (OS), overall progression-free survival (PFS) and hepatic progressio
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems, Inc. (NASDAQ: DCTH) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Delcath Systems, Inc. (NASDAQ: DCTH) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdatePR Newswire
DCTH
Earnings
- 3/26/24 - Beat
DCTH
Sec Filings
- 3/26/24 - Form D
- 3/26/24 - Form 10-K
- 3/26/24 - Form 8-K
- DCTH's page on the SEC website